melanocortin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
== Oxygen-14 == Oxygen-14 (half-life 70.62 seconds) is the second most stable radioisotope of oxygen, and decays by positron emission to nitrogen-14. Oxygen-14 ion beams are of interest to researchers of proton-rich nuclei; for example, one early experiment at the Facility for Rare Isotope Beams in East Lansing, Michigan, produced a 14O beam by proton bombardment of 14N, using it to determine the absolute strength of the electron capture transition.
== History == It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. On 4 July 2011, the European Medicines Agency (EMA) approved a paediatric investigation plan and granted both a deferral and a waiver for canagliflozin (EMEA-001030-PIP01-10) in accordance with EC Regulation No. 1901/2006 of the European Parliament and of the council. It was approved for medical use in the European Union in November 2013. Canagliflozin was approved by the FDA on 29 March 2013, and became the first SGLT2 inhibitor in the United States. Canagliflozin was approved for medical use in Australia in September 2013.
== Impact of narcotics trafficking == In the late 1980s, there continued to be concern about an overburdened and allegedly corrupt judicial system. According to the Department of State's Country Reports on Human Rights Practices for 1988 and Bolivian press reports, judges were implicated in drug-related corruption. Narcotics traffickers routinely tried to bribe judicial and other officials in exchange for releasing suspected smugglers, returning captured drugs, and purging incriminating files. In 1988 the Senate's Constitution and Justice Committee ordered the suspension of thirteen judges of the La Paz, Cochabamba, and Santa Cruz superior district courts of justice for wrongdoing in drug-trafficking cases. The Supreme Court of Justice insisted, however, on its prerogative to try the judges first. After doing so, it ordered the suspension of several of the accused judges and continued to investigate others. Relatively few prosecutions or forfeitures of traffickers' assets took place. A lack of judicial investigatory power hampered the investigation of the bank accounts and the origin of wealth of people suspected of trafficking in drugs. Although thirteen of the "big bosses" reportedly had been identified by early 1988, arrests of drug kingpins were infrequently reported because of lack of evidence.
=== Conservation === Stem cells are being explored for use in conservation efforts. Spermatogonial stem cells have been harvested from a rat and placed into a mouse host and fully mature sperm were produced with the ability to produce viable offspring. Currently research is underway to find suitable hosts for the introduction of donor spermatogonial stem cells. If this becomes a viable option for conservationists, sperm can be produced from high genetic quality individuals who die before reaching sexual maturity, preserving a line that would otherwise be lost.
=== Localized and overall support === Fabric may be used to provide support for the garment by stabilizing weak sections or by creating a backing or lining for the piece. Darning may be utilized on coarsely-woven fabrics with localized areas of damage.
Sources: en.wikipedia.org
=== Radiation processes === Some proponents for the authenticity of the Shroud of Turin have argued that the image on the shroud was created by some form of radiation emission at the "moment of resurrection". However, the STURP member Alan Adler has stated that this theory is not generally accepted as scientific, given that it runs counter to the laws of physics, while agreeing that the darkening of the fabric could be produced by exposure to light (and predicting that despite the fact that the Shroud is normally stored in darkness and rarely displayed, it will eventually become darker in the future). Raymond Rogers also criticized the theory, saying: "It is clear that a corona discharge (plasma) in air will cause easily observable changes in a linen sample. No such effects can be observed in image fibers from the Shroud of Turin. Corona discharges or plasmas made no contribution to image formation." Even if ultraviolet radiation were proven to have formed the image, it cannot be proven that it was not natural, that of the sun, applied to the prepared cloth unevenly to create the image. Others have hypothesized that an earthquake after Jesus’ death could have released a burst of neutrons that irradiated the shroud and changed some of the nuclei to different isotopes by neutron capture.
== Clinical presentation == Patients with hemoglobin H disease present with chronic hemolytic anemia that ranges in severity from mild to moderate disease. Anemia is the most common presenting symptom of patients with HbH disease. Other common clinical features include jaundice, splenomegaly, hepatomegaly, and gallstones. All of these symptoms are related to the destruction of the red blood cells in the spleen and the associated increased hemoglobin metabolism. Patients with non-deletional HbH disease are more likely to be symptomatic and have severe disease presentation when compared to individuals with deletional HbH disease. Disease presentation varies from asymptomatic individuals to neonatal growth retardation and death in the most severe cases. Death in the neonatal period occurs due to the severe anemia resulting in hydrops fetalis. Patients most often present initially due to hemolytic episodes that occur during times of infection or inflammation. During these episodes, patients may develop hemolytic crisis, in which there is a rapid drop in the hemoglobin due to increased red blood cell destruction.
=== Radar cross-section (RCS-)reducing metamaterials === Metamaterials have applications in stealth technology, which reduces RCS in any of various ways (e.g., absorption, diffusion, redirection). Conventionally, the RCS has been reduced either by radar-absorbent material (RAM) or by purpose shaping of the targets such that the scattered energy can be redirected away from the source. While RAMs have narrow frequency band functionality, purpose shaping limits the aerodynamic performance of the target. More recently, metamaterials or metasurfaces have been synthesized that can redirect the scattered energy away from the source using either array theory or generalized Snell's law. This has led to aerodynamically favorable shapes for the targets with the reduced RCS.
=== 19 February === Six people were killed by RSF shelling in Omdurman. The SAF claimed to have retaken the El Hurriya Bridge in central Khartoum, as well as Sidra in North Kordofan. The United Nations confirmed a state of famine in the Zamzam, Abu Shouk and Al Salam IDP camps in North Darfur, as well as in two locations in the Western Nuba Mountains.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.